title: [Pharmacological profile of human-type anti-CD20 antibody ofatumumab (Arzerra(®)) and its clinical study results].
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Yoshizaki
authors.forename: Akira
authors.initials: A
authors.lastname: Tomonari
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000494:pharmacology*; D061067:Antibodies, Monoclonal, Humanized; D000920:Antibody-Dependent Cell Cytotoxicity / Q000187:drug effects / Q000276:immunology; D018951:Antigens, CD20 / Q000276:immunology*; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000494:pharmacology*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D003165:Complement System Proteins / Q000276:immunology; D004195:Disease Models, Animal; D006801:Humans; D007564:Japan; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000276:immunology* / Q000473:pathology; D056910:Republic of Korea
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018951:Antigens, CD20; D000970:Antineoplastic Agents; D003165:Complement System Proteins; C527517:ofatumumab